You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

Investigational Drug Information for TAK-788


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug TAK-788?

TAK-788 is an investigational drug.

There have been 11 clinical trials for TAK-788. The most recent clinical trial was a Phase 1 trial, which was initiated on January 6th 2020.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Liver Diseases. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., Takeda, and Ariad Pharmaceuticals.

There are two US patents protecting this investigational drug and fifty-eight international patents.

Recent Clinical Trials for TAK-788
TitleSponsorPhase
A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788TakedaPhase 2
A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult ParticipantsTakedaPhase 1
A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy KidneysMillennium Pharmaceuticals, Inc.Phase 1

See all TAK-788 clinical trials

Clinical Trial Summary for TAK-788

Top disease conditions for TAK-788
Top clinical trial sponsors for TAK-788

See all TAK-788 clinical trials

US Patents for TAK-788

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-788 ⤷  Sign Up Heteroaryl compounds for kinase inhibition ARIAD PHARMACEUTICALS, INC. (Cambridge, MA) ⤷  Sign Up
TAK-788 ⤷  Sign Up Heteroaryl compounds for kinase inhibition ARIAD Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TAK-788

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-788 Australia AU2015277786 2034-06-19 ⤷  Sign Up
TAK-788 Australia AU2019206024 2034-06-19 ⤷  Sign Up
TAK-788 Brazil BR112016029662 2034-06-19 ⤷  Sign Up
TAK-788 Canada CA2949793 2034-06-19 ⤷  Sign Up
TAK-788 Chile CL2016003222 2034-06-19 ⤷  Sign Up
TAK-788 Chile CL2017003103 2034-06-19 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.